DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/33xrt4/2016_future) has announced the addition of the "2016 Future Horizons and Growth Strategies in the US Clinical Chemistry and Immunodiagnostic Markets: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities" report to their offering.
2016 Future Horizons and Growth Strategies in the US Clinical Chemistry and Immunodiagnostic Markets is a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the US market; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.
The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.
The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
- New product development opportunities with significant market appeal.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
The companies analyzed in the report include
- Beckman Coulter/Danaher
- Biomedical Diagnostics
- Grifols IL
- Kyowa Medex
- Ortho-Clinical Diagnostics
- Thermo Fisher
Tests Analyzed in the Report:
- Routine Clinical Chemistry
- Therapeutic Drug Monitoring (TDM)
- Endocrine Function
- Tumor Markers and Special Chemistry
- Drugs of Abuse
For more information visit http://www.researchandmarkets.com/research/33xrt4/2016_future